GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Illumina ILMN · USD

Health Care · US listing · 🇺🇸 United States

S&P 500

Compare

220.78

+3.59%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Illumina

From its filings with the US Securities and Exchange Commission

SEC filings

Illumina is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ILMN. It is a member of the S&P 500. The SEC classifies its business as laboratory analytical instruments. In the fiscal year to 28 December 2025, it reported revenue of $4.34bn and net income of $850.0m. At that date it held total assets of $6.64bn and shareholders' equity of $2.72bn.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
28 Jul 2000
Employees
8,600
Head office
5200 ILLUMINA WAY, SAN DIEGO, CA, 92122
Incorporated in
DE
Classification
Laboratory Analytical Instruments
Filer status
Large accelerated filer

Leadership

Pay as last reported

  • Dr. Scott GottliebIndependent Chairman of the Board$404,056
  • Mr. Jacob ThaysenChief Executive Officer, Director, since 2023$14.8m
  • Mr. Ankur DhingraChief Financial Officer$5.9m
  • Ms. Patricia LeckmanChief People Officer
  • Dr. Steven BarnardChief Technology Officer$4.0m
  • Mr. Everett CunninghamChief Commercial Officer$10.1m
  • Mr. Kevin PegelsChief of Global Operations$3.8m
  • Mr. Jakob WedelChief Strategy and Corporate Development Officer
  • Mr. Scott DaviesChief Legal Officer, Secretary
  • Dr. Frances ArnoldIndependent Director$400,114
  • Ms. Caroline DorsaIndependent Director$400,114
  • Dr. Robert EpsteinIndependent Director$401,240

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
84
Environment
99
Social
99
Governance
54
Direct emissions (scope 1)
18,836 t
Energy emissions (scope 2)
21,224 t
Value chain emissions (scope 3)
241,938 t
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Illumina Inc. is a leading provider of sequencing and array-based technologies for genetic analysis. The company's strengths include:

Weaknesses

  • Despite its strengths, Illumina Inc. also faces certain weaknesses that could impede its growth and competitiveness:

Opportunities

  • To sustain its growth and expand its business, Illumina Inc. can capitalize on several opportunities:

Threats

  • Illumina Inc. faces certain threats that could impact its market position and profitability:

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.